CTOR · Citius Oncology Inc
United States · RS rating 38 · As of 2026-10-14
| Price | 0.78 USD |
|---|---|
| 1-day change | -1.1% |
| RS rating (overall / 1M / 3M / 12M) | 38 / 27 / 89 / 12 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 24 / 20 / 35 |
| Industry group (rank) | Medical-Generic Drugs (94) |
| EPS growth Q/Q | -350.0% |
| Sales growth Q/Q | -57.7% |
| Distance from 52-week high | +56.2% |
| Market cap (USD) | $86.3M |